Washington, Mar 14 : Researchers from Salk Institute for Biological Studies have identified a molecular pathway that can be a potential therapeutic target for Down's syndrome, the most frequent cause of mental retardation.
The study showed that synaptojanin-1, a central component of the pathway, is essential to production of glia, brain cells that act as neurons'' personal assistants.
Down''s syndrome, spinal cord injury, Alzheimer''s disease, and stroke all are linked by an overproduction of glia.